Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 14;8:153. doi: 10.1038/s41398-018-0201-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Venn diagram illustrating the overlap of 247 genes that were changed in 5XFAD compared to wild type and in 5XFAD mice treated with riluzole compare to untreated mice. b Scatter plot illustrating the 247 overlapping genes showing fold change by 5XFAD (x-axis) against fold change with riluzole treatment on 5XFAD mice (y-axis). 86% of overlapping 5XFAD genes is reversed by riluzole treatment. The upper left quadrant represents 26 genes that had decreased expression with 5XFAD and increased expression after riluzole treatment. Conversely, the lower-right quadrant illustrates 189 genes that were increased with 5XFAD and decreased by riluzole. c The mRNA expression of Mouse APP from RNA-Seq data revealed no significant difference among WT, 5XFAD, and 5XFAD-Riluzole groups. d Histograms illustrating significantly enriched pathways based on genes differentially expressed by overlapping gene. (enrichment score > 1.3). e, f Histograms illustrating significantly enriched pathways with the highest sum enrichment scores across opposite conditions (Increased in 5XFAD and Decreased with riluzole treatment or vice-versa) based on differentially expressed genes (enrichment score > 1.3). Similar pathways and enrichment scores were observed when comparing genes decreased by 5XFAD and increased by riluzole, as well as for genes increased with age and decreased by riluzole. The RNA-Seq data is based on hippocampal tissue pooled into three replicate sequencing libraries/group from WT, n = 10 (pooled 3, 3, 4 mice); 5XFAD, n = 7 (pooled 2, 2, 3 mice); and 5XFAD-Riluzole, n = 8 (pooled 2, 3, 3 mice)